1887

Abstract

Poxvirus vectors represent promising human immunodeficiency virus (HIV) vaccine candidates and were a component of the only successful HIV vaccine efficacy trial to date. We tested the immunogenicity of a novel recombinant capripoxvirus vector, lumpy skin disease virus (LSDV), in combination with modified vaccinia Ankara (MVA), both expressing genes from HIV-1. Here, we demonstrated that the combination regimen was immunogenic in rhesus macaques, inducing high-magnitude, broad and balanced CD4 and CD8 T-cell responses, and transient activation of the immune response. These studies support further development of LSDV as a vaccine vector.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.067835-0
2014-10-01
2019-11-17
Loading full text...

Full text loading...

/deliver/fulltext/jgv/95/10/2267.html?itemId=/content/journal/jgv/10.1099/vir.0.067835-0&mimeType=html&fmt=ahah

References

  1. Amara R. R., Nigam P., Sharma S., Liu J., Bostik V.. ( 2004;). Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. . J Virol 78:, 3811–3816. [CrossRef][PubMed]
    [Google Scholar]
  2. Aspden K., Passmore J. A., Tiedt F., Williamson A. L.. ( 2003;). Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector. . J Gen Virol 84:, 1985–1996. [CrossRef][PubMed]
    [Google Scholar]
  3. Barouch D. H.. ( 2010;). Novel adenovirus vector-based vaccines for HIV-1. . Curr Opin HIV AIDS 5:, 386–390. [CrossRef][PubMed]
    [Google Scholar]
  4. Borthwick N., Ahmed T., Ondondo B., Hayes P., Rose A., Ebrahimsa U., Hayton E. J., Black A., Bridgeman A.. & other authors ( 2013;). Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. . Mol Ther 22:, 464–475. [CrossRef][PubMed]
    [Google Scholar]
  5. Burgers W. A., Shephard E., Monroe J. E., Greenhalgh T., Binder A., Hurter E., Van Harmelen J. H., Williamson C., Williamson A.-L.. ( 2008;). Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C. . AIDS Res Hum Retroviruses 24:, 195–206. [CrossRef][PubMed]
    [Google Scholar]
  6. Burgers W. A., Chege G. K., Muller T. L., van Harmelen J. H., Khoury G., Shephard E. G., Gray C. M., Williamson C., Williamson A. L.. ( 2009;). Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons. . J Gen Virol 90:, 468–480. [CrossRef][PubMed]
    [Google Scholar]
  7. Chege G. K., Burgers W. A., Stutz H., Meyers A., Chapman R., Kiravu A., Bunjun R., Shephard E. G., Jacobs W. R.. & other authors ( 2013;). Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model. . J Virol 87:, 5151–5160. [CrossRef][PubMed]
    [Google Scholar]
  8. de Cassan S. C., Draper S. J.. ( 2013;). Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. . Expert Rev Vaccines 12:, 365–378. [CrossRef][PubMed]
    [Google Scholar]
  9. Garber D. A., O’Mara L. A., Gangadhara S., McQuoid M., Zhang X., Zheng R., Gill K., Verma M., Yu T.. & other authors ( 2012;). Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. . J Virol 86:, 12605–12615. [CrossRef][PubMed]
    [Google Scholar]
  10. García-Arriaza J., Arnáez P., Gómez C. E., Sorzano C. O., Esteban M.. ( 2013;). Improving adaptive and memory immune responses of an HIV/AIDS vaccine candidate MVA-B by deletion of vaccinia virus genes (C6L and K7R) blocking interferon signaling pathways. . PLoS ONE 8:, e66894. [CrossRef][PubMed]
    [Google Scholar]
  11. Gómez C. E., Perdiguero B., García-Arriaza J., Esteban M.. ( 2012a;). Poxvirus vectors as HIV/AIDS vaccines in humans. . Hum Vaccin Immunother 8:, 1192–1207. [CrossRef][PubMed]
    [Google Scholar]
  12. Gómez C. E., Perdiguero B., Nájera J. L., Sorzano C. O., Jiménez V., González-Sanz R., Esteban M.. ( 2012b;). Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. . J Virol 86:, 5026–5038. [CrossRef][PubMed]
    [Google Scholar]
  13. Gudmundsdotter L., Nilsson C., Brave A., Hejdeman B., Earl P., Moss B., Robb M., Cox J., Michael N.. & other authors ( 2009;). Recombinant modified vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. . Vaccine 27:, 4468–4474. [CrossRef][PubMed]
    [Google Scholar]
  14. Haynes B. F., Gilbert P. B., McElrath M. J., Zolla-Pazner S., Tomaras G. D., Alam S. M., Evans D. T., Montefiori D. C., Karnasuta C.. & other authors ( 2012;). Immune-correlates analysis of an HIV-1 vaccine efficacy trial. . N Engl J Med 366:, 1275–1286. [CrossRef][PubMed]
    [Google Scholar]
  15. Keefer M. C., Frey S. E., Elizaga M., Metch B., De Rosa S. C., Barroso P. F., Tomaras G., Cardinali M., Goepfert P., Kalichman A.. ( 2011;). A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. . Vaccine 29:, 1948–1958. [CrossRef][PubMed]
    [Google Scholar]
  16. Kibler K. V., Gomez C. E., Perdiguero B., Wong S., Huynh T., Holechek S., Arndt W., Jimenez V., Gonzalez-Sanz R.. & other authors ( 2011;). Improved NYVAC-based vaccine vectors. . PLoS ONE 6:, e25674. [CrossRef][PubMed]
    [Google Scholar]
  17. Kitching R. P., Hammond J. M., Taylor W. P.. ( 1987;). A single vaccine for the control of capripox infection in sheep and goats. . Res Vet Sci 42:, 53–60.[PubMed]
    [Google Scholar]
  18. Koff W. C., Burton D. R., Johnson P. R., Walker B. D., King C. R., Nabel G. J., Ahmed R., Bhan M. K., Plotkin S. A.. ( 2013;). Accelerating next-generation vaccine development for global disease prevention. . Science 340:, 1232910. [CrossRef][PubMed]
    [Google Scholar]
  19. McElrath M. J., De Rosa S. C., Moodie Z., Dubey S., Kierstead L., Janes H., Defawe O. D., Carter D. K., Hural J.. & other authors ( 2008;). HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis. . Lancet 372:, 1894–1905. [CrossRef][PubMed]
    [Google Scholar]
  20. Penaloza-MacMaster P., Provine N. M., Ra J., Borducchi E. N., McNally A., Simmons N. L., Iampietro M. J., Barouch D. H.. ( 2013;). Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. . J Virol 87:, 1373–1384. [CrossRef][PubMed]
    [Google Scholar]
  21. Perdiguero B., Gómez C. E., Di Pilato M., Sorzano C. O., Delaloye J., Roger T., Calandra T., Pantaleo G., Esteban M.. ( 2013;). Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C. . PLoS ONE 8:, e74831. [CrossRef][PubMed]
    [Google Scholar]
  22. Quinn K. M., Da Costa A., Yamamoto A., Berry D., Lindsay R. W., Darrah P. A., Wang L., Cheng C., Kong W. P.. & other authors ( 2013;). Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. . J Immunol 190:, 2720–2735. [CrossRef][PubMed]
    [Google Scholar]
  23. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M.. & other authors ( 2009;). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. . N Engl J Med 361:, 2209–2220. [CrossRef][PubMed]
    [Google Scholar]
  24. Shen Y. J., Shephard E., Douglass N., Johnston N., Adams C., Williamson C., Williamson A. L.. ( 2011;). A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV). . Virol J 8:, 265. [CrossRef][PubMed]
    [Google Scholar]
  25. Shephard E., Burgers W. A., Van Harmelen J. H., Monroe J. E., Greenhalgh T., Williamson C., Williamson A. L.. ( 2008;). A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice. . AIDS Res Hum Retroviruses 24:, 207–217. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.067835-0
Loading
/content/journal/jgv/10.1099/vir.0.067835-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error